Table 3 Analysis of the impact of potential confounders of the autoimmune disease-30-day mortality association
Adjusting for confounders of the association between autoimmune disease and 30-day mortality | OR (95% CI) | P value | Magnitude of confounding |
|---|---|---|---|
No confounders adjusted (“crude”) | 0.71 (0.58–0.86) | < 0.001 | – |
Age adjusted | 0.74 (0.60–0.90) | 0.003 | − 4.46% |
Sex adjusted | 0.71 (0.60–0.86) | < 0.001 | − 0.31% |
Race adjusted | 0.71 (0.58–0.87) | < 0.001 | − 0.93% |
Documented bacteremia adjusted | 0.68 (0.56–0.83) | < 0.001 | 4.41% |
Infection site adjusted | 0.72 (0.56–0.83) | 0.001 | − 1.39% |
SOFA score adjusted | 0.81 (0.65–1.00) | 0.051 | − 12.34% |
Elixhauser comorbidity index adjusted | 0.71 (0.57–0.86) | < 0.001 | 0.26% |
DMARD or prednisone usage adjusted | 0.66 (0.54–0.81) | < 0.001 | 7.58% |
ICU care unit adjusted | 0.71 (0.58–0.86) | < 0.001 | 0.10% |